Comments
Sun Pharmaceutical Industries on Friday announced interim results from a Phase 2 study of interleukin-23 (IL-23) inhibitor, ILUMYA™, in patients with active psoriatic arthritis. It was presented in a late-breaking oral presentation at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain.
The interim analysis revealed that over 71 per cent of patients treated with Ilumya experienced a 20 per cent improvement in joint and skin symptoms, meeting the primary endpoint of the study. “To help us determine the potential of ILUMYA™ across psoriatic disease, we are now exploring a possible Phase 3 trial for psoriatic arthritis with regulatory authorities,” it said in a statement to the exchanges. The stock climbed 0.58 per cent at ₹392.35 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.